miR‑125b regulates the drug‑resistance of breast cancer cells to doxorubicin by targeting HAX‑1

Hu,Guinv; Zhao,Xiaokang; Wang,Jiang; Lv,Liting; Wang,Chaoqun; Feng,Liang; Shen,Liangqiong; Ren,Weili

doi:10.3892/ol.2017.7476

miR‑125b regulates the drug‑resistance of breast cancer cells to doxorubicin by targeting HAX‑1

Authors:
- Guinv Hu
- Xiaokang Zhao
- Jiang Wang
- Liting Lv
- Chaoqun Wang
- Liang Feng
- Liangqiong Shen
- Weili Ren
View Affiliations

Affiliations: Department of Breast Surgery, Dongyang People's Hospital, Jinhua, Zhejiang 322100, P.R. China, Department of Breast Surgery, Shaoxing Shangyu People's Hospital, Shaoxing, Zhejiang 312300, P.R. China
Published online on: November 23, 2017 https://doi.org/10.3892/ol.2017.7476
Pages: 1621-1629
Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MircroRNAs (miRNAs) are considered as essential regulators in the tumorigenesis and chemoresistance of multiple cancer types. In the present study, it was demonstrated that the expression levels of miR‑125b were significantly downregulated in the tissues of patients with breast cancer (BC), as well as the BC cell lines in vitro. To study the association between chemoresistance and miR‑125b in BC, doxorubicin (DOX)‑resistant MCF‑7 (MCF‑7/R) cells were established, and gain‑ and loss‑of‑function experiments were performed. It was demonstrated that the overexpression of miR‑125b increased the sensitivity of MCF‑7/R cells to DOX. Furthermore, it was revealed that the sensitization of miR‑125b mimics to DOX‑induced cell death was regulated by the hematopoietic cell‑specific protein 1‑associated protein X‑1 (HAX‑1) vector and HAX‑1 small interfering RNA. These results emphasized the notable function of miR‑125b and its target of HAX‑1 in regulating DOX‑resistance. In addition, it was demonstrated that the miR‑125b mimics promoted the loss of the mitochondrial membrane potential and the generation of reactive oxygen species induced by DOX treatment in MCF‑7/R cells. These data suggest that the miR‑125b‑HAX‑1‑mitochondria pathway has a notable function in the treatment of DOX‑resistant BC cells, which may provide a novel target for the chemotherapy of BC.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Du XL, Key CR, Osborne C, Mahnken JD and Goodwin JS: Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med. 138:90–97. 2003. View Article : Google Scholar : PubMed/NCBI
3	Chen YY, Li ZZ, Ye YY, Xu F, Niu RJ, Zhang HC, Zhang YJ, Liu YB and Han BS: Knockdown of SALL4 inhibits the proliferation and reverses the resistance of MCF-7/ADR cells to doxorubicin hydrochloride. BMC Mol Biol. 17:62016. View Article : Google Scholar : PubMed/NCBI
4	Wang H, Yu Y, Jiang Z, Cao WM, Wang Z, Dou J, Zhao Y, Cui Y and Zhang H: Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis. Sci Rep. 6:264562016. View Article : Google Scholar : PubMed/NCBI
5	Chen NT, Wu CY, Chung CY, Hwu Y, Cheng SH, Mou CY and Lo LW: Probing the dynamics of doxorubicin-DNA intercalation during the initial activation of apoptosis by fluorescence lifetime imaging microscopy (FLIM). PLoS One. 7:e449472012. View Article : Google Scholar : PubMed/NCBI
6	Zheng Y, Lv X, Wang X, Wang B, Shao X, Huang Y, Shi L, Chen Z, Huang J and Huang P: MiR-181b promotes chemoresistance in breast cancer by regulating Bim expression. Oncol Rep. 35:683–690. 2016. View Article : Google Scholar : PubMed/NCBI
7	Chakravarty G, Mathur A, Mallade P, Gerlach S, Willis J, Datta A, Srivastav S, Abdel-Mageed AB and Mondal D: Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells. Biochimie. 124:53–64. 2016. View Article : Google Scholar : PubMed/NCBI
8	Ambros V: MicroRNA pathways in flies and worms: Growth, death, fat, stress, and timing. Cell. 113:673–676. 2003. View Article : Google Scholar : PubMed/NCBI
9	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
10	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
11	Tan YY, Xu XY, Wang JF, Zhang CW and Zhang SC: MiR-654-5p attenuates breast cancer progression by targeting EPSTI1. Am J Cancer Res. 6:522–532. 2016.PubMed/NCBI
12	Gu X, Xue JQ, Han SJ, Qian SY and Zhang WH: Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer. Cancer Biomark. 16:395–403. 2016. View Article : Google Scholar : PubMed/NCBI
13	Ye Z, Hao R, Cai Y, Wang X and Huang G: Knockdown of miR-221 promotes the cisplatin-inducing apoptosis by targeting the BIM-Bax/Bak axis in breast cancer. Tumour Biol. 37:4509–4515. 2016. View Article : Google Scholar : PubMed/NCBI
14	Zhou S, Huang Q, Zheng S, Lin K, You J and Zhang X: miR-27a regulates the sensitivity of breast cancer cells to cisplatin treatment via BAK-SMAC/DIABLO-XIAP axis. Tumour Biol. 37:6837–6845. 2016. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Wang J, Tian X, Han R, Zhang X, Wang X, Shen H, Xue L, Liu Y, Yan X, Shen J, et al: Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer. Oncogene. 33:1181–1189. 2014. View Article : Google Scholar : PubMed/NCBI
17	Prathapan A, Vineetha VP and Raghu KG: Protective effect of Boerhaavia diffusa L. against mitochondrial dysfunction in angiotensin II induced hypertrophy in H9c2 cardiomyoblast cells. PLoS One. 9:e962202014. View Article : Google Scholar : PubMed/NCBI
18	Duan W, Jin X, Li Q, Tashiro S, Onodera S and Ikejima T: Silibinin induced autophagic and apoptotic cell death in HT1080 cells through a reactive oxygen species pathway. J Pharmacol Sci. 113:48–56. 2010. View Article : Google Scholar : PubMed/NCBI
19	Radhika V, Onesime D, Ha JH and Dhanasekaran N: Galpha13 stimulates cell migration through cortactin-interacting protein Hax-1. J Biol Chem. 279:49406–49413. 2004. View Article : Google Scholar : PubMed/NCBI
20	Zorov DB, Juhaszova M and Sollott SJ: Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev. 94:909–950. 2014. View Article : Google Scholar : PubMed/NCBI
21	Zhao X, He W, Li J, Huang S, Wan X, Luo H and Wu D: MiRNA-125b inhibits proliferation and migration by targeting SphK1 in bladder cancer. Am J Transl Res. 7:2346–2354. 2015.PubMed/NCBI
22	Lee M, Kim EJ and Jeon MJ: MicroRNAs 125a and 125b inhibit ovarian cancer cells through post-transcriptional inactivation of EIF4EBP1. Oncotarget. 7:8726–8742. 2016. View Article : Google Scholar : PubMed/NCBI
23	Yin W, Nie Y, Zhang Z, Xie L and He X: miR-193b acts as a doxorubicin sensitizer via the caspase-3-dependent pathway in HCC chemotherapy. Oncol Rep. 34:368–3674. 2015. View Article : Google Scholar : PubMed/NCBI
24	Lv L, An X, Li H and Ma L: Effect of miR-155 knockdown on the reversal of doxorubicin resistance in human lung cancer A549/dox cells. Oncol Lett. 11:1161–1166. 2016.PubMed/NCBI
25	Tang XY, Zheng W, Ding M, Guo KJ, Yuan F, Feng H, Deng B, Sun W, Hou Y and Gao L: miR-125b acts as a tumor suppressor in chondrosarcoma cells by the sensitization to doxorubicin through direct targeting the ErbB2-regulated glucose metabolism. Drug Des Devel Ther. 10:571–583. 2016.PubMed/NCBI
26	Clarke R, Leonessa F and Trock B: Multidrug resistance/P-glycoprotein and breast cancer: Review and meta-analysis. Semin Oncol. 32(6 Supp 7): S9–S15. 2005. View Article : Google Scholar : PubMed/NCBI
27	Suzuki Y, Demoliere C, Kitamura D, Takeshita H, Deuschle U and Watanabe T: HAX-1, a novel intracellular protein, localized on mitochondria, directly associates with HS1, a substrate of Src family tyrosine kinases. J Immunol. 158:2736–2744. 1997.PubMed/NCBI
28	Trebinska A, Högstrand K, Grandien A, Grzybowska EA and Fadeel B: Exploring the anti-apoptotic role of HAX-1 versus BCL-XL in cytokine-dependent bone marrow-derived cells from mice. FEBS Lett. 588:2921–2927. 2014. View Article : Google Scholar : PubMed/NCBI
29	Trebinska A, Rembiszewska A, Ciosek K, Ptaszynski K, Rowinski S, Kupryjanczyk J, Siedlecki JA and Grzybowska EA: HAX-1 overexpression, splicing and cellular localization in tumors. BMC Cancer. 10:762010. View Article : Google Scholar : PubMed/NCBI
30	Halestrap AP, Clarke SJ and Javadov SA: Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardioprotection. Cardiovasc Res. 61:372–385. 2004. View Article : Google Scholar : PubMed/NCBI